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Abstract
Background
It is well known that chronic inflammation plays a pivotal role in the development of hepatitis
B virus (HBV) related hepatocellular carcinoma (HCC). However, the causes behind aber-
rant expression of inflammation-related genes occurred in HCC remain unclear.
Methods
We performed array-based analyses to comprehensively investigate the contributions of
DNA methylation and somatic copy number aberration (SCNA) to the aberrant expression
of 1,027 inflammation-related genes in 30 HCCs and paired non-tumor tissues. The results
were validated in public datasets and an additional sample set of 47 paired HCCs and non-
tumor tissues.
Results
We identified 252 differentially expressed, 125 aberrantly methylated and 287 copy number
changed inflammation-related genes. Despite reasonable statistical power, among them,
only 11 genes and 56 genes whose aberrant expression was associated with DNA methyla-
tion or SCNA, respectively. DNA methylation and SCNA together contributed to less than
30% aberrant expression of inflammation-related genes.
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Conclusion
These results suggest that molecular mechanisms other than DNA methylation and SCNA
might play major role in the regulation of aberrant expression of inflammation-related gene
in HBV-related HCCs.
Introduction
Hepatocellular carcinoma (HCC) is one of the most common cancers in the world. The major
risk factors for the development of HCC include infection with hepatitis B virus (HBV) or hep-
atitis C virus (HCV), aflatoxin exposure, and chronic alcohol abuse [1]. It has been reported
that about 55% of HCC occurs in China, where the major etiological factor is chronic HBV in-
fection [2]. HCC is one clear example of inflammation-related cancers, with chronic inflamma-
tion being indispensable in its development. It has been shown that chronic liver inflammation
due to persistent HBV or HCV infection may lead to cirrhosis, which can eventually progress
to HCC at an incidence rate that is 4–5 times higher than that among asymptomatic HBV car-
riers [3].
During the past decades, evidence has been accumulated to show that dysregulation of in-
flammation-related genes plays important roles in the development of HCCs [4, 5]. It was re-
ported that both chromosomal aberrations such as copy number loss or gain and epigenome
deregulation by DNAmethylation, histone modification and non-coding RNAs may contrib-
ute to the aberrant expression of inflammation-related genes [6–9]. However, current knowl-
edge is mainly derived from incomplete studies focusing on only single or a few such genes,
using either a candidate gene or genome-wide approach. To the best of our knowledge, there
are few, if any, comprehensive studies employing integrative analysis to simultaneously inter-
rogate both genetic and epigenetic events contributing to the aberrant expression of genes in
the inflammation pathway in HBV-related HCCs.
In this current study, we used high throughput array-based technology to comprehensively
analyze the relationship between DNA methylation or somatic copy number aberration
(SCNA) and aberrant expression of 1,027 genes in the inflammation pathway [10] in HBV-re-
lated HCCs. We validated our array-based results in public datasets and in an additional sam-
ple set of HCCs and paired non-tumor tissues. Our data indicated that DNA methylation and
SCNA indeed cause some inflammation-related genes to be aberrantly expressed, but they only
contribute about 30% aberrant expression of these genes in HBV-related HCCs.
Materials and Methods
HCC samples
In this study, we performed a two-stage analysis in total up to 77 HCCs and their paired non-
tumor tissues (more than 2 cm from tumor). In brief, 30 HCCs and their paired non-tumor
specimens were randomly selected for the discovery phase and the rest 47 HCCs and their
paired non-tumor tissues were used for the validation phase. All tumor and their paired non-
tumor tissues were obtained from hepatectomy of patients with HCC between 2010 and 2013
at Cancer Hospital, Chinese Academy of Medical Sciences (Beijing). The samples were imme-
diately frozen in liquid nitrogen upon surgically resected. The diagnosis of HCC was all con-
firmed by histopathology. We selected the samples for HBV positive but HCV negative
according to serology tests and infection history. Patients who had received chemotherapy or
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radiotherapy were excluded from this study. We also collected clinical characteristics of each
subject in this study, which are shown in S1 Table. All patients signed an informed consent and
this study was approved by the Institutional Review Board of the Chinese Academy of Medical
Sciences Cancer Institute.
Arrays used in the discovery phase
In the discovery phase, high-throughput screening was performed using Affymetrix Human
Gene 1.0 ST Array (Affymetrix, Santa Clara, CA), Nimblegen 3×720 K CpG Island Plus RefSeq
Promoter Array (Roche NimbleGen, Madison, WI) and Affymetrix GeneChip Human Map-
ping 6.0 array (Affymetrix) to measure mRNA expression, DNAmethylation and copy number
changes in HCCs and paired non-tumor specimens, respectively. Referring to the correspond-
ing array design database, we confirmed that the Affymetrix Human Gene 1.0 ST Array inter-
rogates all 1,027 inflammation-related genes described by Loza et al. [10] with 1,108
transcripts; and the Nimblegen 3×720 K CpG Island Plus RefSeq Promoter Array and Affyme-
trix GeneChip Human Mapping 6.0 array interrogate 38,179 probes covering 1,024 genes and
33,855 probes covering 938 genes, respectively.
Array-based data production
Total RNA samples were extracted from 30 fresh HCCs and paired non-tumor tissues using
the Trizol reagent (Life Technologies, Carlsbad, CA). Genome-wide transcriptional profiling
was produced using Affymetrix Human Gene 1.0 ST Array according to the manufacturer's
protocol. Arrays were processed in two batches; one included 10 arrays, and the other included
20 arrays. Raw data were first processed using Robust Multiarray Averaging [11] and batch ef-
fect was adjusted using ComBat [12]. Adjusted expression values were used in subsequent
downstream analysis.
Genomic DNA samples were isolated from the same 30 fresh HCCs and paired non-tumor
specimens using a commercial DNeasy Blood & Tissue Kit (QIAGEN, Valencia, CA). Each
DNA sample was then divided into two portions. One portion was bisulfite-converted using
the EZ DNAMethylation kit (Zymo Research, Irvine, CA), and the DNA methylation profiles
was obtained with the MeDIP-chip platform based on the Nimblegen 3×720 K CpG Island
Plus RefSeq Promoter Array according to the manufacturer's protocol. Arrays were also pro-
cessed in two batches in the same manner as afore-described for gene expression quantifica-
tion. The pre-processing of DNAmethylation array data was similar to that used for gene
expression array data. We first normalized the raw data using control probes designed in the
methylation array, and then adjusted batch effect with ComBat.
The other portion of genomic DNA sample was used to detect DNA copy number aberra-
tions using the Affymetrix GeneChip Human Mapping 6.0 set according to the manufacturer's
protocol. Affymetrix Power Tools was used on the raw data to generate signal intensities,
which were further analyzed by PennCNV [13] to call probe-based copy numbers. Log R ratios
(LRR) estimated by PennCNV were carried forward for further analysis.
Array-based data analysis
Paired student's t-test was used to determine whether the difference in gene expression, DNA
methylation or copy numbers of inflammation-related genes between HCC tissues and
matched non-tumor liver tissues is significant. Bonferroni adjustment was used to correct for
multiple comparisons in view of 1,108 transcripts, 38,179 methylation probes, and 33,855
SNP/CN probes covering inflammation-related genes; therefore, P values<4.5×10–5,
<1.3×10–6 and<1.48×10–6 were considered to be statistically significant, respectively, for
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transcripts, methylation and copy number. In this study, significant methylation probes cover-
ing the same gene locus all showed effect in the same direction, except for the 2 significant
probes covering the FYN gene. Therefore, we calculated the mean methylation value of all sig-
nificant probes across the same gene for further gene-level DNA methylation analysis. As to
the FYN gene, the 2 significant probes were both taken forward for separate further analysis.
Because of tumor heterogeneity, the abundance and size of SCNA often vary across different
patients with HCC or even across different tumor cells from the same tissue. Besides, although
several analytical programs have been established to detect SCNAs based on the intensity of
SNP array probes, the results obtained by using these programs are not all consistent. There-
fore, in this study, we used a simple spanning strategy similar to that described by Abecasis
[14] to detect structure variant using PCR. Under this strategy, only DNA regions that contain
at least 2 adjacent SNP/CN probes showing significant difference between tumor and paired
normal tissue were considered as SCNAmarkers. For significant probes exhibiting changes in
the same direction at one gene locus, gene level mean LRR value across the significant probes
was used for further analysis. For probes exhibiting changes in opposite directions at the same
gene locus, mean LRR values across the significant probes were separately calculated for each
direction and carried forward for further analysis. Spearman correlation coefficient was used to
test the correlation between gene expression and DNA methylation or copy numbers for
each gene.
Validation using public dataset
Public datasets, GSE14520 and GSE25097, or GSE37988 and GSE54503 datasets, together with
our data, were used to identify the overlapping genes reported by array-based gene expression
or DNA methylation. The processed datasets of GSE14520, GSE25097, GSE37988 and
GSE54503 were extracted from GEO database (http://www.ncbi.nlm.nih.gov/geo/), and ana-
lyzed by GEO2R software. Student's t-test was used to examine the difference in aberrant ex-
pression or DNAmethylation changes of inflammation-related genes in HCCs with
Bonferroni corrected significance threshold. In addition, we validated the SCNA results in the
GSE38323 dataset, and validated the correlation between gene expression and SCNA in the
published GSE28127 dataset [15,16].
Validation in the independent sample
An independent sample, consisting of 47 surgically removed HCC and paired non-tumor spec-
imens, was used to further validate our findings from the discovery stage.
Total RNA isolated from each tissue specimen was converted to cDNA using oligo(dT)15
primer and SuperScriptII (Invitrogen, Grand Island, NY). mRNA levels were measured by
quantitative real-time PCR (RT-PCR) on an ABI Prism 7900 sequence detection system (Ap-
plied Biosystems, Foster City, CA) using the SYBR Green method. mRNA levels of the candi-
date genes were calculated relative to expression of GAPDH.
Methylation profile was determined in genomic DNA isolated from each tissue specimen.
Primers targeting the promoter regions or CpG islands of the candidate inflammation-related
genes were designed as described by Wojdacz et al. [17]. Tissue DNA samples, commercial
fully methylated DNA and unmethylated DNA (Zymo Research) were simultaneously con-
verted by bisulfite. A series of methylation dilution standards of 100%, 75%, 50%, 25%, 10%,
5% and 0% were prepared to depict methylation standard curve by mixing methylated DNA
and unmethylated DNA. RT-PCR and methylation-sensitive high resolution melting
(MS-HRM) analysis were carried out on an ABI Prism 7900 sequence detection system.
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RT- PCR based on SYBR Green method was used to examine copy numbers of the candi-
date genes in each genomic DNA sample, with the LINE-1 gene, the most abundant retrotran-
sposon in the human genome as the reference [18]. Copy numbers of the candidate genes were
calculated relative to those of LINE-1 in each sample.
Paired student's t-test was used to examine the differences in gene expression, DNAmethyl-
ation and copy numbers, at a false discovery rate (FDR) of 0.05. All the primers used in the val-
idation are shown in S2 Table.
Gene network construction
Inflammation-related genes with expression changes tallying with DNA methylation changes
or copy number changes were selected to construct gene networks using the MetaCore data-
base and software (GeneGo, Inc.; http://thomsonreuters.com/metacore/).
Results
Identification of aberrant expression, methylation and SCNA in
inflammation-related genes
We first obtained the profiles of mRNA expression, DNAmethylation and copy number
changes of all inflammation-related genes utilizing the array-based techniques. Overall, we
identified 260 transcripts covering 252 inflammation-related genes that exhibited substantially
aberrant expression in HCCs. Among them, 121 transcripts (114 genes) were up-regulated
while 139 (138 genes) were down-regulated (S3 Table). We then performed exploratory hierar-
chical clustering of the 260 transcripts and found that the expression profiles in tumors and ad-
jacent non-tumor tissues created unequivocally separate clusters (Fig 1A, left). We found 71
probes residing in 39 inflammation-related gene loci were hypermethylated in HCCs, 391
probes in 85 genes hypomethylated. In addition, there were two differentially methylated
probes in the FYN gene with one hypermethylated and the other hypomethylated (S4 Table).
Hierarchical clustering resulted in overall clear distinction between tumor and adjacent non-
tumor tissues, except for 3 samples (Fig 1A,middle). As to copy number profiles, we identified
131 inflammation-related genes (consistent evidence from 512 probes) showing significant
copy number gain and 141 genes (consistent evidence from 617 probes) showing significant
copy number loss in HCC tumor tissues. In addition, 117 probes showed significant copy num-
ber difference between tumor and non-tumor tissues, exhibiting effects in both directions
across 15 genes (S5 Table). Hierarchical clustering based on copy number resulted in clear dis-
tinction between tumor and non-tumor tissues (Fig 1A, right).
Contribution of methylation and SCNA to aberrant expression of
inflammation-related genes
To investigate the contributions of DNAmethylation and SCNA to the aberrant expression of
inflammation-related genes, we integrated the expression profiles and DNA methylation pro-
files or copy number profiles obtained from tumors and non-tumor tissues. We found that 42
genes with aberrant expression had aberrant DNA methylation in HCCs compared with paired
non-tumor tissues. Among them, only 8 genes with substantial down-regulation had DNA
hypermethylation and 3 genes with substantial over-expression had DNA hypomethylation
(Fig 1B and 1C), indicating a possible minor role (<5% of total) of DNAmethylation in the ex-
pression regulation of these inflammation-related genes. We observed essential segregation of
the expression levels and DNA methylation values in tumor and non-tumor tissues (Fig 1C).
For the correlation between gene expression and SCNA, we found 56 genes with aberrant
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expression had concomitant SCNA in HCCs. Of these 56 genes, 26 with over-expression had
copy number gain, while 30 with down-regulation had DNA deletion; SCNA can explain only
one-fifth of aberrant expression of inflammation-related genes in HCCs (Fig 1D and 1E). The
essential segregation of the gene expression levels and DNA copy number values is shown in
Fig 1E. We found a negative correlation between the expression levels and DNA methylation
for 11 genes (Fig 2A and S6 Table) and a positive correlation between the expression levels and
copy numbers for 56 genes (Fig 2B and S7 Table). Interestingly, not only aberrant DNAmeth-
ylation but also SCNA contribute to the aberrant expression of BCL2, ESR1, FYN, PRKCB, and
PTPN13 in HCCs.
Fig 1. Identification of inflammation-related genes exhibiting coordinative changes betweenmRNA expression and DNAmethylation or SCNA in
HBV-related HCCs. (a) Hierarchical clustering with 260 significant transcripts corresponding 252 genes (left), 464 significant methylation probes covering
125 genes (middle), or 1,246 significant SNP/CN probes covering 287 genes (right) across HCCs (Tumor) and paired non-tumor tissues (Control). (b) Venn
diagram showing 42 overlapping genes identified by the analysis of both mRNA expression and DNAmethylation. EXP, genes with aberrant expression;
METH, genes with aberrant DNAmethylation. (c) Starburst plot of 42 overlapping genes identified by the analysis of both gene expression and DNA
methylation. Red, blue and green dots indicate the genes hypermethylated and down-regulated, the genes hypomethylated and up-regulated and the genes
having their expression not associated with DNAmethylation, respectively. (d) Venn diagram showing 71 overlapping genes identified by the analysis of both
mRNA expression and SCNA. EXP, genes with aberrant expression; SCNA, genes with copy number aberration. (e) Starburst plot of 71 overlapping genes
identified by the analysis of both mRNA expression and SCNA. Red, blue and green dots indicate the genes with copy number gain and up-regulated
expression, the genes with copy number deletion and down-regulated expression and the genes having inverse relationship between SCNA and mRNA
expression, respectively.
doi:10.1371/journal.pone.0126836.g001
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Fig 2. Relationship betweenmRNA expression and DNAmethylation (a) or SCNA (b) of the randomly selected inflammation-related genes. Tumor,
HCCs; Control, paired no-tumor tissues.
doi:10.1371/journal.pone.0126836.g002
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Validation of methylation and SCNA relevant to aberrant inflammation-
related gene expression
There are currently no published integrative analyses on the relationship between aberrant ex-
pression of inflammation-related genes and DNAmethylation or SCNA in HCCs. To fill in
this gap, we investigated the overlapping genes with aberrant expression and aberrant DNA
methylation or SCNA in our dataset and the public datasets. Of the 252 aberrantly expressed
genes found in our study, 200 (79.4%) and 204 (81.0%) were verified in the GSE14520 (S8
Table) and GSE25097 (S9 Table) dataset, which totaled up to 237 (94.1%) in at least one dataset
(Fig 3A). As to the 125 aberrantly methylated genes identified in our study, 110 (88.0%) and 47
Fig 3. Venn diagram of the overlapping inflammation-related genes having significant mRNA
expression (a), or DNAmethylation (b) in HBV-related HCCs in our study with public datasets. EXP,
genes with aberrant expression; METH, genes with aberrant methylation.
doi:10.1371/journal.pone.0126836.g003
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(37.6%) were also found to be aberrantly methylated in the GSE54503 (S10 Table) and
GSE37988 (S11 Table) dataset, respectively, totaling up to 88.8% in at least one dataset (Fig
3B). We compared SCNA identified in our study with that in the GSE38323 dataset, and found
that among the 287 genes with SCNA, 68 (23.7%) were also reported in the public dataset. In
addition, as to the 56 genes with aberrant expression and concomitant SCNA identified in our
study, 17 (30.4%) were found in GSE28127.
We next randomly selected 8 genes aberrantly expressed in HCCs that had aberrant DNA
methylation (CR1, ESR1, PTPN13, and SOCS2) or SCNA (C8A, CXCL14, ITGA6 andMARCO)
to validate the array-based results in an independent sample set consisting 47 HCCs and paired
non-tumor specimens. The array-based analysis in our discovery stage showed that for
PTPN13 and SOCS2, the methylation sites are located in the CpG islands but for CR1 and ESR1
the methylation sites are located in the intronic and promoter regions. MS-HRM was used to
measure methylation at these 4 genes in the validation sample set and standard curves are
shown in S1 Fig. We found substantial changes of both DNA methylation and mRNA expres-
sion of CR1, ESR1, PTPN13, and SOCS2 in HCCs compared with paired non-tumor tissues
(Fig 4A), which is consistent with the results obtained by analyzing the array data in our dis-
covery sample. Similarly, we were able to validate the association between SCNA and gene ex-
pression of C8A, CXCL14, ITGA6 andMARCO (Fig 4B).These validation experiments indicate
that the results produced by array-based analysis are reliable.
Functional network construction
We used MetaCore database and software to investigate the possible functional networks of in-
flammation-related genes suffering from aberrant DNA methylation (11 genes, S6 Table) or
SCNA (56 genes, S7 Table) in HCCs. For the genes suffering from aberrant methylation, the
top functional network (gScore = 76.97) involved in the following GO processes: response to al-
cohol, response to organic cyclic compound, immune response-regulating cell surface receptor
signaling pathway, response to steroid hormone stimulus and immune response-regulating sig-
naling pathway, using PKC-β, Bcl-2, FAP-1, ESR and PKC as key nodes (Fig 5A and S12
Table). For the genes suffering from SCNA, the top functional network (gScore = 271.81) in-
volved in the GO processes of immune response-regulating signaling pathway, Fc receptor sig-
naling pathway, innate immune response, regulation of immune system process and regulation
of immune response, using FLT3, GRB2, TCF8, β-catenin, and Fyn as key nodes (Fig 5B and
S13 Table). Noticeably, the functional network of the genes suffering from aberrant methyla-
tion is distinct from that of the genes suffering from SCNA, suggesting that methylation and
SCNA contribute to different inflammation processes which may have the different regulatory
mechanism (S2 Fig).
Discussion
It is well known that chronic inflammation induced by HBV plays a pivotal role in the develop-
ment of HCC [19, 20]. Many efforts have been made to investigate the aberrant expression and
the regulatory mechanisms of inflammation-related genes in HBV-related HCC, but most have
focused on a single or few genes. In this study, we performed a two-stage analysis to systemati-
cally investigate the contributions of aberrant DNAmethylation and SCNA to the aberrant ex-
pression of genes in the whole inflammation system.
We identified 252 differentially expressed, 125 aberrantly methylated and 287 copy number
changed inflammation-related genes in HBV-related HCC, which were validated in several
published datasets. Except for the GSE54503 dataset, all the other five referred datasets were
obtained from Chinese patients with HCC, which may efficiently reduce ethnic bias for
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Fig 4. Validation of mRNA expression, DNAmethylation and copy number variation of the randomly selected inflammation-related genes in 47
samples. (a) Validations of mRNA expression and DNAmethylation of CR1, ESR1, PTPN13 and SOCS2. TSS, transcription start site; Tumor, HCCs;
Control, paired non-tumor tissues. Arrows represent the validation primers. Blue dots represent the significant methylation probes designed in array. Green
bars represent the CpG island. (b) Validation of gene expression and copy number variation of C8A, CXCL14, ITGA6 andMARCO.
doi:10.1371/journal.pone.0126836.g004
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comparison analysis. Most of the differentially expressed genes (94.1%) and aberrantly methyl-
ated genes (88.8%) were found in at least one referred dataset, indicating consistent results
among these studies and ours. However, only 23.7% of copy number-changed genes identified
in our study were also identified in the published report of GSE38323, probably due to different
array platforms and methods used to detect SCNA across studies.
The most significant result in the current study is that we integrated the expression profile
with DNA methylation or SCNA profiles to investigate to what extent the aberrant expression
of these inflammation genes is attributable to methylation or SCNA. We found that among the
252 aberrantly expressed inflammation genes in HCC, only 11 genes whose aberrant expres-
sion can be explained by change in methylation; and only 56 genes whose aberrant expression
can be explained by SCNA. It has been well known that aberrant DNA methylation is one of
the most crucial hallmarks of carcinogenesis. However, our results revealed that aberrant DNA
methylation might play a minor role (<5%) in the transcriptional regulation of inflammation-
related genes in HBV-related HCCs. Previous studies have shown that aberrant DNAmethyla-
tion of inflammation-related genes comes into existence in liver cirrhosis and some are main-
tained in HCCs [21, 22]. These findings are in agreement with the notion that both aberrant
DNAmethylation and inflammatory response occur as early events in HCC carcinogenesis. It
has been reported that structure aberrations are persistently accumulated from early to late
stage of HCCs [23]. Our results indicated that SCNA might explain one-fifth aberrant expres-
sion of inflammation genes in HBV-related HCCs. Taken together, aberrant DNAmethylation
Fig 5. The functional network of top inflammation-related genes created by integrative analysis of mRNA expression associated with aberrant
DNAmethylation (a) and SCNA (b) in HBV-related HCCs. Blue circles represent the key nodes of the network.
doi:10.1371/journal.pone.0126836.g005
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and SCNAs in HBV-related HCCs contributed to less than 30% aberrant expression of inflam-
mation-related genes. Furthermore, analysis of functional networks of aberrantly expressed
genes showed that aberrant DNA methylation and SCNA brought about different inflammato-
ry response pathways. All these findings suggested that the regulatory system of inflammation-
related genes is complicated and meticulous. Other molecular mechanisms such as transcrip-
tion factors, non-coding RNAs and mutations might be more relevant in terms of aberrant ex-
pression of inflammation-related genes in HCCs, which warrants future investigation.
Four genes (CR1, ESR1, PTPN13, and SOCS2) that showed aberrant expression associated
with DNA methylation were randomly selected to verify in an additional sample set and
proved to be consistent with array-based results. CR1, a negative regulator of the complement
cascade, has been reported to be hypermethylated in acute lymphoblastic leukemia [24]. ESR1,
a ligand-activated transcription factor, has been shown to be hypermethylated in the promoter
in 83.3% of HCC samples [25]. PTPN13 is a protein tyrosine phosphatase gene that is frequent-
ly down-regulated and hypermethylated in HCC cell lines [26]. SOCS2, encoding the suppres-
sor of cytokine signaling protein, is frequently hypermethylated in primary ovarian cancer
[27]. Similarly, the association between SCNA and aberrant expression of C8A, CXCL14,
ITGA6 andMARCO was also verified in the validation sample set. The CXCL14 gene, whose
copy number was significantly lower in HCCs compared with paired non-tumor tissues, en-
codes a chemokine that has been shown to play a pivotal role as a tumor suppressor in HCC
[28]. However, the roles that C8A, ITGA6 andMARCO genes play in the development of HCC
remain unclear and further studies on these genes are under way.
We acknowledge some limitations of this study. Although tissue heterogeneity of the liver is
much less than other tissues such as the lung and the breast, which provides good opportunity
for analysis of gene expression in cancer tissue, the stromal content in clinical samples might
also have potential to affect mRNA analysis of HCC. Besides, this study analyzed only the
mRNA levels and it would be profited to analyze the protein level of some genes to confirm
their mRNA levels.
In summary, our two-stage comprehensive study achieved at least two progresses: identifi-
cation of HCC-specific DNAmethylation, SCNA and mRNA expression profiles of inflamma-
tion-related genes and elucidation of the contribution of DNAmethylation and SCNA to the
aberrant expression of inflammation-related genes in HBV-related HCCs. These results par-
tially answered the long-standing question, i.e., what mechanism contributes to the aberrant
expression of inflammation-related genes that play important roles in the development of
HBV-related HCCs.
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